316 related articles for article (PubMed ID: 12920163)
1. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.
Kim KA; Lee JS; Park HJ; Kim JW; Kim CJ; Shim IS; Kim NJ; Han SM; Lim S
Life Sci; 2004 Apr; 74(22):2769-79. PubMed ID: 15043991
[TBL] [Abstract][Full Text] [Related]
3. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo Z; Raeissi S; White RB; Stevens JC
Drug Metab Dispos; 1997 Mar; 25(3):390-3. PubMed ID: 9172960
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
6. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
Newton DJ; Wang RW; Lu AY
Drug Metab Dispos; 1995 Jan; 23(1):154-8. PubMed ID: 7720520
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
12. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.
Chatterjee P; Franklin MR
Drug Metab Dispos; 2003 Nov; 31(11):1391-7. PubMed ID: 14570772
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of cytostatically active 6-aminobenzo[c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes.
Zebothsen I; Kunze T; Clement B
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):37-43. PubMed ID: 16867169
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone.
Kitamura A; Mizuno Y; Natsui K; Yabuki M; Komuro S; Kanamaru H
Biopharm Drug Dispos; 2005 Mar; 26(2):59-65. PubMed ID: 15619261
[TBL] [Abstract][Full Text] [Related]
15. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.
Kasahara M; Suzuki H; Komiya I
Drug Metab Dispos; 2000 Apr; 28(4):409-17. PubMed ID: 10725309
[TBL] [Abstract][Full Text] [Related]
16. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
Desta Z; Soukhova N; Mahal SK; Flockhart DA
Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
18. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
19. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
20. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]